Nasdaq · Common Stock · Services-Commercial Physical & Biological Research
American pharmaceutical company
28 entities across 18 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-10 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Escient Pharmaceuticals, Inc. | Delaware | |
| Escient Pharmaceuticals Australia Pty Ltd | Australia | |
| Incyte Holdings Corporation | Delaware | |
| Incyte Real Estate Holdings I LLC | Delaware | |
| Incyte Real Estate Holdings II LLC | Delaware | |
| Incyte Research Institute LLC | Delaware | |
| Villaris Therapeutics Inc. | Delaware | |
| Incyte International Holdings Corporation | Delaware | |
| Incyte Biosciences Canada Corporation | Canada | |
| Incyte International Holdings S.à r.l. | Luxembourg | offshore centre |
| Incyte Biosciences International S.à r.l. | Switzerland | |
| Incyte Biosciences Austria GmbH | Austria | |
| Incyte Biosciences Denmark ApS | Denmark | |
| Incyte Biosciences Finland Oy | Finland | |
| Incyte Biosciences France | France | |
| Incyte Biosciences Germany GmbH | Germany | |
| Incyte Biosciences Italy S.R.L. | Italy | |
| Incyte Biosciences Distribution B.V. | Netherlands | |
| Incyte Biosciences Benelux B.V. | Netherlands | |
| Incyte Biosciences Norway AS | Norway | |
| Incyte Biosciences Iberia S.L. | Spain | |
| Incyte Biosciences Nordic AB | Sweden | |
| Incyte Biosciences Poland sp. z o.o. | Poland | |
| Incyte Biosciences Technical Operations S.à r.l. | Switzerland | |
| Incyte Biosciences Australia Pty Ltd | Australia | |
| Incyte Biosciences Japan G.K. | Japan | |
| Incyte Biosciences (Shanghai) Co., Ltd. | China | |
| Jidochem S.à r.l. | Switzerland |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $2.7B | −$295.7M | −$312.0M | — | 218,073,000 |
| FY2021 | $3.0B | $948.6M | $568.5M | — | 222,074,000 |
| FY2022 | $3.4B | $340.7M | $892.1M | — | 223,958,000 |
| FY2023 | $3.7B | $597.6M | — | — | 225,928,000 |
| FY2024 | $4.2B | $32.6M | — | — | 210,530,000 |
| FY2025 | $5.1B | $1.3B | — | — | 200,700,000 |
14 institutions tracked — 8 added, 5 reduced, 1 opened a new position, 1 sold out.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BlackRock, Inc. | Index | 18,032,718 | −945,480 | $2.0B |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 5,320,901 | −487,029 | $603.2M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 409,514 | −342,342 | $46.4M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 3,575,521 | +309,385 | $405.3M |
| JPMORGAN CHASE & CO | Active fund | 809,690 | +252,648 | $92.8M |
| BANK OF AMERICA CORP /DE/ | Active fund | 676,191 | −239,336 | $76.7M |
| FMR LLC | Active fund | 1,381,773 | +208,883 | $156.6M |
| CITADEL ADVISORS LLC | Hedge fund | 298,009 | +162,325 | $33.8M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 3,512,132 | −139,400 | $398.1M |
| MORGAN STANLEY | Active fund | 2,948,364 | +98,036 | $334.2M |
| STATE STREET CORP | Index | 9,722,336 | +80,952 | $1.1B |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 4,750,735 | +47,551 | $536.5M |
| Bridgewater Associates, LP | Hedge fund | 168,253 | +37,957 | $19.1M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
INCYTE CORP files under SIC 8731 — all 3 services-commercial physical & biological research companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
